Liraglutide Use in Children with Obesity

Introduction to Liraglutide Therapy

• The American Academy of Pediatrics and other guideline societies recommend liraglutide 3.0 mg as an adjunct to lifestyle modification for adolescents aged 12 years and older with obesity, after lifestyle interventions have failed or in the presence of severe complications 1, 2

Age-Specific Indications and Approval Status

• Liraglutide 3.0 mg is approved for use in adolescents ≥12 years with obesity in several countries, according to the American Academy of Pediatrics 1, 2
• A phase 3 trial in 251 adolescents (12 to <18 years) demonstrated significant BMI standard-deviation score reduction of -0.22 compared to placebo (P = 0.002) over 56 weeks, as reported by the Obesity Society 1

Clinical Criteria for Initiating Therapy

• The American Heart Association recommends that pharmacotherapy, including liraglutide, should only be considered when lifestyle modification has been ineffective or in the presence of severe obesity-related complications 1, 2
• Pharmacotherapy must always be used as an adjunct to behavioral change, never as monotherapy, as stated by the American Academy of Pediatrics 1, 2

Dosing Protocol

• The American Diabetes Association recommends starting at 0.6 mg subcutaneously once daily for 7 days, increasing by 0.6 mg weekly, with a target maintenance dose of 3.0 mg subcutaneously once daily for obesity 3
• The gradual titration minimizes gastrointestinal adverse effects, according to the Gastroenterology society 3

Efficacy Monitoring and Discontinuation Criteria

• The Endocrine Society recommends discontinuing liraglutide if <4% body weight loss after 16 weeks of treatment or if BMI or BMI z-score reduction is <4% after 12 weeks at maximum dose 1, 2

Safety Profile and Adverse Effects

• The American Academy of Pediatrics reports that gastrointestinal adverse events are the most common, occurring in 64-80% of pediatric patients, with nausea and vomiting being particularly frequent 1, 3

Critical Monitoring Requirements

• The American Heart Association recommends close pediatric monitoring to identify adverse effects, including monitoring for gastrointestinal symptoms, weight/BMI, and renal function, particularly given case reports of acute kidney injury and liver injury in adolescents 1, 2, 3

Important Clinical Considerations

• The Gastroenterology society recommends that liraglutide should not be used with other GLP-1 receptor agonists or DPP-4 inhibitors 4, 3

Comparison to Other Pediatric Obesity Medications

• The Obesity Society reports that orlistat is also approved for adolescents >12 years but produces more modest BMI reduction (0.55-0.8 kg/m²) compared to liraglutide 1, 2
• The American Academy of Pediatrics states that metformin can cause weight loss but lacks long-term efficacy data for obesity without diabetes 1, 2

Evidence Quality and Limitations

• The 2023 consensus guidelines from the Obesity Society provide the most recent and comprehensive guidance on pediatric obesity pharmacotherapy, with high-quality phase 3 RCT data existing for adolescents 12 to <18 years 1, 2
• Emerging 2025 data now support use in younger children (6 to <12 years), representing the newest evidence, according to the American Academy of Pediatrics [1, 2

Common Pitfalls to Avoid

• The American Heart Association recommends not using liraglutide as first-line therapy, but rather after lifestyle modification has been attempted first, and not continuing therapy beyond 12-16 weeks if inadequate weight loss response (<4%) 1, 2
• The Gastroenterology society advises not skipping the gradual titration schedule, as this increases GI adverse effects 3